John Knopf resumes & CV records
Resumes
John Knopf
John Knopf
John Knopf
John Knopf
John Knopf
John Knopf
John Knopf
John L Knopf, Age 72Marthas Vineyard, MA
John Knopf Phones & Addresses
Edgartown, MA
Auburndale, MA
147 Robbins Dr, Carlisle, MA 01741 (978) 369-9020 (978) 369-9098
La Quinta, CA
3 Forest Ln, Smithtown, NY 11787 (631) 265-3143 (631) 265-0186
Durham, NC
Acton, MA
Riverside, CA
147 Robbins Dr, Carlisle, MA 01741 (978) 270-7755
Work
Position:
Executive, Administrative, and Managerial Occupations
Emails
Mentions for John L Knopf
Publications & IP owners
Us Patents
Cytosolic Phospholipase A2-Gamma Enzymes And Polynucleotides Encoding Same
US Patent:
6440683, Aug 27, 2002
Filed:
Feb 8, 1999
Appl. No.:
09/246290
Inventors:
Chuanzheng Song - Brighton MA
Ronald Kriz - Hudson MA
John Knopf - Acton MA
Ronald Kriz - Hudson MA
John Knopf - Acton MA
Assignee:
Genetics Institute L.L.C. - Cambridge MA
International Classification:
C12Q 134
US Classification:
435 18, 435198, 4352523, 4353201, 435 692, 536 232, 530350
Abstract:
The invention provides a novel calcium-independent cytosolic phospholipase A -Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Inhibitors Of Phospholipase Enzymes
US Patent:
6500853, Dec 31, 2002
Filed:
Oct 11, 2000
Appl. No.:
09/686616
Inventors:
Jasbir S. Seehra - Lexington MA
John C. McKew - Arlington MA
Frank Lovering - Acton MA
Jean E. Bemis - Arlington MA
YiBin Xiang - Acton MA
Lihren Chen - Cambridge MA
John L. Knopf - Acton MA
John C. McKew - Arlington MA
Frank Lovering - Acton MA
Jean E. Bemis - Arlington MA
YiBin Xiang - Acton MA
Lihren Chen - Cambridge MA
John L. Knopf - Acton MA
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
A61K 31405
US Classification:
514415, 548509, 548250, 514339, 514381, 5462774
Abstract:
This invention concerns compounds and pharmaceutical compositions useful for treating or preventing inflammatory conditions in a mammal, the methods comprising administration of novel pharmaceutically useful compounds of the general formulae: or pharmaceutically acceptable salts thereof, wherein R -R are as defined in the specification.
Cytosolic Phospholipase A-Gamma Enzymes And Polynucleotides Encoding Same
US Patent:
6979565, Dec 27, 2005
Filed:
Jul 8, 2002
Appl. No.:
10/191780
Inventors:
Chuanzheng Song - Brighton MA, US
Ronald Kriz - Hudson MA, US
John Knopf - Acton MA, US
Ronald Kriz - Hudson MA, US
John Knopf - Acton MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
C12N009/20
C12N001/20
C12N015/00
C07H021/04
C07K001/00
C12N001/20
C12N015/00
C07H021/04
C07K001/00
US Classification:
435198, 4352523, 4353201, 435 18, 536 232, 530300, 530350
Abstract:
The invention provides a novel calcium-independent cytosolic phospholipase A-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Cerberus/Coco Derivatives And Uses Thereof
US Patent:
7316998, Jan 8, 2008
Filed:
May 27, 2005
Appl. No.:
11/140024
Inventors:
John Knopf - Carlisle MA, US
Jasbir Seehra - Lexington MA, US
Jasbir Seehra - Lexington MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
C07K 14/00
US Classification:
514 2, 530350, 530351
Abstract:
The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
Alk7 And Myostatin Inhibitors And Uses Thereof
US Patent:
7456149, Nov 25, 2008
Filed:
Mar 2, 2005
Appl. No.:
11/071686
Inventors:
John Knopf - Carlisle MA, US
Jasbir Seehra - Lexington MA, US
Jasbir Seehra - Lexington MA, US
Assignee:
Acceleron Pharma, Inc. - Cambridge MA
International Classification:
A61K 38/16
C12N 15/11
C12N 15/13
C12N 15/11
C12N 15/13
US Classification:
514 2, 514 12, 4241331, 4241781, 435 697
Abstract:
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
Gdf3 Propeptides And Related Methods
US Patent:
7465706, Dec 16, 2008
Filed:
Jun 24, 2005
Appl. No.:
11/165963
Inventors:
John Knopf - Carlisle MA, US
Jasbir Seehra - Lexington MA, US
Jasbir Seehra - Lexington MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 38/00
A61K 38/16
C07K 14/00
C12N 15/00
A61K 38/16
C07K 14/00
C12N 15/00
US Classification:
514 12, 514 2, 530350, 435 691, 435 697, 4241981
Abstract:
In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
Il-13 Binding Agents
US Patent:
7501121, Mar 10, 2009
Filed:
Jun 17, 2005
Appl. No.:
11/155843
Inventors:
Lioudmila Tchistiakova - Andover MA, US
Marion T. Kasaian - Charlestown MA, US
Debra D. Donaldson - Medford MA, US
Xiang-Yang Tan - Reading MA, US
Davinder Gill - Burlington MA, US
Macy X. Jin - Reading MA, US
Bruce Jacobson - Framingham MA, US
Samuel J. Goldman - Acton MA, US
John Knopf - Carlisle MA, US
Angela M. Widom - Acton MA, US
Marion T. Kasaian - Charlestown MA, US
Debra D. Donaldson - Medford MA, US
Xiang-Yang Tan - Reading MA, US
Davinder Gill - Burlington MA, US
Macy X. Jin - Reading MA, US
Bruce Jacobson - Framingham MA, US
Samuel J. Goldman - Acton MA, US
John Knopf - Carlisle MA, US
Angela M. Widom - Acton MA, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/395
C07K 16/24
C07K 16/24
US Classification:
4241391, 5303879, 5303873
Abstract:
Agents (e. g. , antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
Lefty Polypeptides And Derivatives Thereof
US Patent:
7612040, Nov 3, 2009
Filed:
Jun 30, 2006
Appl. No.:
11/479181
Inventors:
John Knopf - Carlisle MA, US
Jasbir Seehra - Lexington MA, US
Ravindra Kumar - Shrewsbury MA, US
Jasbir Seehra - Lexington MA, US
Ravindra Kumar - Shrewsbury MA, US
Assignee:
Acceleron Pharma Inc. - Cambridge MA
International Classification:
A61K 38/16
A61K 38/18
A61K 38/19
C07K 14/00
C07K 14/475
C07K 14/51
A61K 38/18
A61K 38/19
C07K 14/00
C07K 14/475
C07K 14/51
US Classification:
514 12, 514 2, 530350
Abstract:
The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.